Q2 2023 · 13F-HR
Finepoint Capital LPholdings as filed
Filed 2023-08-11 · accession 0000904454-23-000482
$289.1M
Reported value
37
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $22.0M | 7.62% | 241,690 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $21.7M | 7.50% | 317,300 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $20.3M | 7.02% | 846,953 | Common | SOLE |
| 78667J108 | SG7 | SAGE THERAPEUTICS INC | $16.8M | 5.82% | 357,765 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $16.7M | 5.76% | 1,325,775 | Common | SOLE |
| 36315X101 | LKFT | GALAPAGOS NV | $16.5M | 5.72% | 406,859 | Common | SOLE |
| 61775R105 | MORFUSD | MORPHIC HOLDING INC | $16.5M | 5.70% | 287,556 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $16.0M | 5.52% | 608,628 | Common | SOLE |
| 15678U128 | CERE1EUR | CEREVEL THERAPEUTICS HLDNG I | $15.7M | 5.42% | 492,545 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $15.4M | 5.33% | 302,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $14.4M | 4.97% | 797,527 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $14.4M | 4.97% | 125,457 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $12.5M | 4.32% | 139,772 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $12.0M | 4.17% | 369,093 | Common | SOLE |
| G21810109 | CLVT | CLARIVATE PLC | $11.9M | 4.11% | 1,247,406 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $11.7M | 4.05% | 761,721 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $10.2M | 3.53% | 411,500 | Common | SOLE |
| 071734107 | BHC | BAUSCH HEALTH COS INC | $9.3M | 3.22% | 1,165,000 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $8.8M | 3.05% | 701,570 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $5.0M | 1.74% | 961,251 | Common | SOLE |
| G33032122 | — | ARES ACQUISITION CORP | $403,765 | 0.14% | 504,706 | Common | SOLE |
| G1355U121 | — | BRIDGETOWN HOLDINGS LTD | $221,960 | 0.08% | 895,000 | Common | SOLE |
| 17144T115 | — | CHURCHILL CAPITAL CORP V | $110,221 | 0.04% | 612,000 | Common | SOLE |
| 17143W119 | — | CHURCHILL CAPITAL CORP VI | $97,200 | 0.03% | 540,000 | Common | SOLE |
| 320703119 | CLDWW | FIRST LIGHT ACQUISITION GROUP INC | $85,176 | 0.03% | 655,200 | Common | SOLE |
| 17144M110 | — | CHURCHILL CAPITAL CORP VII | $76,720 | 0.03% | 548,000 | Common | SOLE |
| G7641C114 | — | ROSS ACQUISITION CORP II | $74,435 | 0.03% | 439,666 | Common | SOLE |
| G2476C123 | CDAWF | COMPASS DIGITAL ACQUISITION CORP | $68,434 | 0.02% | 459,906 | Common | SOLE |
| G63836111 | IVCPW | SWIFTMERGE ACQUISITION CORP | $48,020 | 0.02% | 490,000 | Common | SOLE |
| 56608A113 | — | MARBLEGATE ACQUISITION CORP | $41,307 | 0.01% | 735,000 | Common | SOLE |
| G01109126 | — | AFTERNEXT HEALTHTECH ACQUISITION CORP | $31,753 | 0.01% | 366,666 | Common | SOLE |
| 21289P110 | — | CONYERS PARK III ACQUISITION CORP | $28,583 | 0.01% | 571,666 | Common | SOLE |
| G9845F117 | LSBWF | YS BIOPHARMA CO LTD | $23,030 | 0.01% | 489,999 | Common | SOLE |
| 20607U116 | CNDAW | CONCORD ACQUISITION CORP II | $16,333 | 0.01% | 408,333 | Common | SOLE |
| 43734R111 | — | HOME PLATE ACQUISITION CORP | $14,697 | 0.01% | 690,000 | Common | SOLE |
| 09001T114 | — | BILANDER ACQUISITION CORP | $9,334 | 0.00% | 183,749 | Common | SOLE |
| G2540H116 | — | CORSAIR PARTNERING CORP | $0 | — | 334,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.